Show simple item record

dc.contributor.authorBooton, Richard
dc.contributor.authorWard, Timothy H
dc.contributor.authorHeighway, Jim
dc.contributor.authorTaylor, Pat
dc.contributor.authorPower, Fiona
dc.contributor.authorAshcroft, Linda
dc.contributor.authorMorris, Julie
dc.contributor.authorThatcher, Nick
dc.date.accessioned2009-07-07T15:46:00Z
dc.date.available2009-07-07T15:46:00Z
dc.date.issued2006-06-01
dc.identifier.citationXeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. 2006, 106 (11):2421-7 Canceren
dc.identifier.issn0008-543X
dc.identifier.pmid16649224
dc.identifier.doi10.1002/cncr.21885
dc.identifier.urihttp://hdl.handle.net/10541/72863
dc.description.abstractBACKGROUND: The treatment of lung cancer has reached a therapeutic plateau. Several mechanisms of platinum resistance have been described, including the removal of platinum-DNA adduct by nucleotide excision repair (NER). Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy. The authors investigated the relation between XPD polymorphisms and treatment response, toxicity, and overall survival in patients who received platinum-based chemotherapy for advanced nonsmall cell lung cancer (NSCLC). METHODS: Between 2001 and 2002, 108 patients with chemotherapy-naive, advanced NSCLC were recruited. Associations between XPD312/751 polymorphisms and XPD haplotype and treatment response, toxicity. and survival were evaluated. RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype. CONCLUSIONS: The XPD haplotype may represent a useful pharmacogenomic marker of platinum-based chemotherapy in patients with advanced NSCLC and requires prospective validation.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshDNA Repair
dc.subject.meshFemale
dc.subject.meshGenotype
dc.subject.meshHaplotypes
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshSurvival Rate
dc.subject.meshXeroderma Pigmentosum Group D Protein
dc.titleXeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital National Health Service Trust, Manchester, United Kingdom. r.booton@btopenworld.comen
dc.identifier.journalCanceren
refterms.dateFOA2020-09-17T12:07:52Z
html.description.abstractBACKGROUND: The treatment of lung cancer has reached a therapeutic plateau. Several mechanisms of platinum resistance have been described, including the removal of platinum-DNA adduct by nucleotide excision repair (NER). Polymorphisms within the Xeroderma pigmentosum Group D protein (XPD), a member of the NER pathway, are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy. The authors investigated the relation between XPD polymorphisms and treatment response, toxicity, and overall survival in patients who received platinum-based chemotherapy for advanced nonsmall cell lung cancer (NSCLC). METHODS: Between 2001 and 2002, 108 patients with chemotherapy-naive, advanced NSCLC were recruited. Associations between XPD312/751 polymorphisms and XPD haplotype and treatment response, toxicity. and survival were evaluated. RESULTS: Significant correlations were observed between XPD haplotype and Grade 4 neutropenia and overall survival together with a greater response to platinum-based chemotherapy for the XPD *A haplotype. CONCLUSIONS: The XPD haplotype may represent a useful pharmacogenomic marker of platinum-based chemotherapy in patients with advanced NSCLC and requires prospective validation.


Files in this item

Thumbnail
Name:
cncr.21885.pdf
Size:
105.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record